Arthritis Clinical Trials in Chicago

View 59 new treatments for Arthritis in Chicago, IL, and nearby areas, such as Naperville. Every day, Power helps hundreds of arthritis patients connect with leading medical research.
View 83 trials in Chicago
Filter (83)

NSAIDs for Knee Osteoarthritis

Research Clinic, Chicago + 1 more

This trial is testing naproxen, a common pain reliever, in people with painful knee osteoarthritis. Naproxen helps reduce swelling and pain by blocking certain chemicals in the body. Participants will receive naproxen to compare its effects. Naproxen has been shown to be an effective and well-tolerated drug for the treatment of osteoarthritis of the hip and knee in previous studies.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Thomas J Schnitzer, MD, PhD
Principal Investigator

Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis

Eli Lilly Clinic, Chicago + 2 more

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Guselkumab for Psoriatic Arthritis

Janssen Clinic, Hinsdale + 2 more

This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

COVID-19 Vaccines for Rheumatic Diseases

Research Clinic, Chicago + 1 more

Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Pain Medication for Knee Osteoarthritis

Research Clinic, Chicago + 1 more

This is a clinical trial of people who have pain due to knee osteoarthritis at Northwestern University Feinberg School of Medicine. The study will last for about 20 weeks. 180 qualified participants will be randomly assigned in a 1:1:1 ratio (60 participants per group) to one of three treatment groups: duloxetine, celecoxib, or placebo. Participants will have an Xray, knee MRI, brain MRI, blood draws, pain sensitivity testing, and asked to fill out questionnaires. The purpose of this study is to try to predict which participants will respond to the treatment.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Thomas J Schnitzer, MD, PhD
Principal Investigator

Baricitinib for Rheumatoid Arthritis

Eli Lilly Clinic, Schaumburg + 4 more

This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

TG-C for Knee Osteoarthritis

Kolon TissueGene Clinic, Chicago + 4 more

This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
David W Romness, MD
Principal Investigator

Tildrakizumab for Psoriatic Arthritis

Sun Clinic, Skokie + 4 more

This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Non-Surgical Interventions for Knee Osteoarthritis

Research Clinic, Chicago + 1 more

There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Steven Cohen, MD
Principal Investigator

Upadacitinib for Axial Spondyloarthritis

AbbVie Clinic, Skokie + 3 more

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). * To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). * To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2). * To evaluate the maintenance of disease control after withdrawal of upadacitinib.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
Page 1 of 9

Frequently Asked Questions

How much do arthritis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do arthritis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across arthritis trials in Chicago, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for arthritis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Chicago is research being conducted for arthritis?

Prominent hospitals in Chicago conducting arthritis clinical trials include Northwestern University and Rush University Medical Center, each with approximately 14 trials. Trials are also active in the Ravenswood neighborhood on the north side, with around 3 trials as of 2024.

What promising new drugs are being tested?

In Chicago, arthritis research includes treatments like Janus Kinase (JAK) Inhibitors and Monoclonal Antibodies. Notable specific interventions being studied are Upadacitinib, Guselkumab, and Autologous Bone Marrow Aspirate Concentrate.